Livanova (Nasdaq:LIVN) announced today that it began the commercial launch of its Essenz patient monitor.
London-based LivaNova launched the Essenz patient monitor, which uses a patient-tailored approach to improve efficiency and quality of care during cardiopulmonary bypass (CPB) procedures, in the U.S. and Europe, having recently received both FDA 510(k) clearance and CE mark approval.
The company began the initial targeted launch in U.S. and European hospitals that were involved in the platform’s design and development program, according to a news release.
LivaNova said it designed the patient monitor to provide decision-making support for the perfusionist during the entire CPB procedure with compatibility with the LivaNova S5 heart-lung machine. It will be a feature of the complete Essenz perfusion system as well, which the company expects to launch in stages later this year.
Features of the Essenz monitor include intraoperative quality indicator threshold and GDP modules to allow individualized patient management strategy, as well as an intuitive graphical user interface that displays patient parameters continuously during a case.
“The Essenz Patient Monitor is the result of an intense user-centric design process we have undertaken with perfusionists,” LivaNova Cardiopulmonary President Marco Dolci said in the release. “We worked to combine the clinical wisdom of perfusionists with our Company’s legacy of providing safe and reliable cardiopulmonary equipment. As we look forward to the launch of the complete Essenz Perfusion System, we are eager to usher in a new era of perfusion where advanced interpretation of data provides greater value and support to perfusionists as they perform life-saving duties.”